TUESDAY, SEPTEMBER 27, 2016

Imaxio announces use of antigen re-engineering in TB vaccine trial

Imaxio SA, a French biopharmaceutical company, recently announced that its proprietary pro-immunogenic technology was administered for the first time to humans in a Phase I clinical trial for a tuberculosis vaccine candidate.

Imaxio administered its IMX313 technology in a Phase I dose escalation study meant to assess the safety and immunogenicity of the MVA85A-IMX313 TB vaccine. The study is being conducted at the Jenner Institute at Oxford University in England.

"Following a number of successes with IMX313 in preclinical trials, we are really pleased to have reached this milestone: the first administration of IMX313 to human," Fergal Hill, the chief scientific officer of Imaxio, said. "We believe strongly that this will confirm fully that IMX313 is a real solution for developing more effective human vaccines and for addressing major infectious diseases."

IMX313 is meant to enhance the immune response for each vaccine in which it is used. The technology was developed to increase the effectiveness of some human and animal vaccine candidates. The currently available TB vaccine, Bacillus Calmette-Guerin, is largely ineffective at protecting against pulmonary TB in endemic areas.

Helen McShane, a professor of vaccinology at the Jenner Institute, will perform the study.

"We are keen to find out whether this novel vaccine candidate will pave the way for new successes in addressing tuberculosis," McShane said. "We think IMX313 may be a key component to help MVA85A show even greater potency in humans."

Worldwide, there are approximately two million deaths annually from tuberculosis.